NCT04104139View on ClinicalTrials.gov

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 11, 2019

Primary Completion Date

September 25, 2024

Study Completion Date

May 31, 2025

Conditions
Rectal AdenocarcinomaStage IIA Rectal Cancer AJCC v8Stage IIB Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIA Rectal Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8Stage IIIC Rectal Cancer AJCC v8
Interventions
RADIATION

3-Dimensional Conformal Radiation Therapy

Undergo 3D-CRT

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

DRUG

Trifluridine and Tipiracil Hydrochloride

Given PO

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

lead

OHSU Knight Cancer Institute

OTHER